2026 · 2nd Quarter (Apr 1 - June 30)
Filed by CHILDREN'S HEALTHCARE OF ATLANTA.
Open official filingSource-reported fields
Expense method: A
Literal source text
Section 340B Drug Pricing Program Sickle cell disease research funding generally Drug pricing reforms generally Mental and behavioral health legislation generally Federal telehealth policy generally H.R. 2107 (Children's Hospital GME Support Reauthorization Act of 2025), all provisions
Literal federal measure citations: H.R. 2107
Autism research programs and autism intervention programs generally, including Medicaid coverage of detection methodologies. Department of Health and Human Services programs regarding autism and sickle cell disease research H.R. 9260 (Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027) Title II, regarding Children's Hospitals Graduate Medical Education (CHGME) program, National Institutes of Health funding, sickle cell disease research, and other programs related to pediatric healthcare. Implementation of H.R.1, Sections 71115, 71116, regarding Medicaid funding.
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.
